Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Edge 'Devastated' By Phase III Failure of EG-1962, Set To Downsize

Executive Summary

Company announces plans for layoffs after Phase III NEWTON 2 study of EG-1962 for subarachnoid hemorrhage goes up in smoke.

You may also be interested in...

Edge's Aneurysm Drug Cuts Hospital Stays, Improves Outcomes

Edge Therapeutics Inc. reported on Feb. 19 during the International Stroke Conference (ISC) in Los Angeles on that EG-1962 cut 3.5 days from time spent in the intensive care unit (ICU) and doubled the likelihood of favorable outcomes for patients with aneurysmal subarachnoid hemorrhage (aSAH).

New Nimodipine Formulation Aimed At Reducing Fatal Medication Errors

Nymalize, an oral formulation of brain hemorrhage treatment nimodipine, aims to minimize serious risks associated with incorrect administration of older forms of the drug.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts